An interventional study of Uterine manipulator use in Endometrial Neoplasms, sponsored by Universita di Verona. Recruiting at 3 sites in Italy. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Endometrial Neoplasms with a site in Italy — 70 open to participants now, 87 under way, 16 of them phase 3. Endometrial Neoplasms · Italy.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, this one is the 5th largest by planned enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2023, is one of 19 with no phase, reaches primary completion later than 84 of the 86 other live ones, and was the 69th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →70 of the 139 studies in Endometrial Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+ · Women only
Eikon Therapeutics · Sites in Italy, United States, Australia and 12 more countries
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 21–75 · Women only
Genmab · Sites in Italy, United States, Australia and 16 more countries
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 39 · Phase 3 27 · Phase 4 1
First in 1988; this study’s year is marked. 21 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,030 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 290 across the 96 interventional studies, 200 across the 42 observational. Of the 40 that completed or were terminated, 11 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 139 have an industry lead sponsor. The 10 most frequent:
Universita di Verona is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
Universita di Verona has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Endometrial Neoplasms with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06790004Azienda USL Reggio Emilia - IRCCSEndometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy) | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06963385Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoRadiomics and Molecular Classification in Endometrial Cancer | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Minimally invasive surgery is the recommended approach in endometrial cancer (EC) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes. The uterine manipulator is commonly used in benign and malignant pathologies to perform a laparoscopic or robotic hysterectomy. However, although regularly used, the uterine manipulator adoption in EC is a controversial technical aspect due to the raised concerns regarding the possible risk of disruption of the tumor mass, the spread of malignant cells, and seeding of the disease, particularly at the level of the vaginal cuff or spread of tumor cells, with increased risk of recurrence and death due to EC. On that basis, given that hysterectomy without a uterine manipulator is feasible, only a randomized controlled trial comparing oncologic outcomes in EC patients after use versus not use of the uterine manipulator will be able to provide high-quality evidence to answer this critical question and allow or exclude the use of a uterine manipulator during minimally invasive hysterectomy for EC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total hysterectomy with bilateral salpingo-oophorectomy performed with the use of a uterine manipulator during surgery.
Device: Uterine manipulator use
Total hysterectomy with bilateral salpingo-oophorectomy performed without the use of a uterine manipulator during surgery.
The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
Recurrence-free survival
Any recurrence or death related to endometrial cancer (EC) or treatment
Time frame: Each follow-up visit, up to 4 years from the day of surgery
Cause-specific survival
Any death related to endometrial cancer (EC) or treatment
Time frame: Each follow-up visit, up to 4 years from the day of surgery
Overall survival
Any death for any cause
Time frame: Each follow-up visit, up to 4 years from the day of surgery
Site-specific recurrence-free survival
Any recurrence per site of first recurrence
Time frame: Each follow-up visit, up to 4 years from the day of surgery
Operative time
Time between first incision and skin closure
Time frame: Day of surgery
Intraoperative blood loss
Total blood aspirate during the surgical procedure
Time frame: Day of surgery
30-day post-surgical morbidity
Perioperative (intraoperative and postoperative) complications graded based on the Clavien-Dindo classification
Time frame: 30 days after surgery
Lymphovascular space invasion
Presence of lymphovascular space invasion at definitive pathology
Time frame: Day of surgery
Peritoneal cytology
Presence of positive peritoneal cytology at definitive pathology
Time frame: Day of surgery
Quality of life indexes
The Functional Assessment of Cancer Therapy - General (FACT-G) - A 27-item questionnaire designed to measure four domains of Health-Related Quality of Life in cancer patients: Physical, social, emotional, and functional well-being. Score range 0-108. The higher the score, the better the Quality of Life.
Time frame: Each follow-up visit, up to 4 years from the day of surgery
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Dec 2031, 107 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 107 months is above that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.